AMPAkines Archives

Banerjee team at College of Staten Island

Correcting Fragile X Syndrome Deficits by Targeting Neonatal PKCε Signaling in the Brain

February 17, 2022

Enhancing PKCε in early development normalized oxytocin, AMPAR signaling, and adult behavior in Fragile X mice, highlighting PKCε as a promising therapeutic target.

Cellular-Specific Therapeutic Targeting of Inhibitory Circuits in Fragile X Syndrome

April 21, 2021

The team studied how inhibitory brain circuits malfunction in Fragile X and tested ways to restore balance by targeting mGluR and endocannabinoid signaling.

Auditory Dysfunction in Fragile X Syndrome in a Mouse Model of Fragile X

April 5, 2021

FRAXA-funded studies found Fragile X mice show altered auditory circuit function with delayed startle timing and reduced prepulse inhibition, mirroring human sound sensitivity.

Clinical Trials and Cyclic AMP in Fragile X Syndrome: A Life Journey

March 10, 2021

In November 2020, a phase II clinical trial reported extremely successful results. This clinical trial of a PDE4D inhibitor from Tetra Pharmaceuticals was conducted by Dr. Elizabeth Berry-Kravis at Rush University Medical Center and funded by FRAXA Research Foundation. In this Simons Foundation lecture, Elizabeth Berry-Kravis traces 30 years of Fragile X research, from identifying its cause, through finding dozens of treatment targets, through a series of disappointing clinical trials.

Nazim Kourdougli and Carlos Portera-Cailleau

Correcting Sensory Processing in Fragile X Mice by Modulating Kv3.1

June 19, 2019

FRAXA funded UCLA research on a Kv3.1-targeting drug to ease sensory issues in Fragile X. This work built on Yale-led work now also being pursued by Autifony Therapeutics.

Developmental Profile of Glutamatergic Synapses in Fragile X

May 2, 2019

A FRAXA fellowship helped reveal how glutamate receptors at synapses develop differently in Fragile X, offering clues to improve learning and memory.

Enhancing NMDA Receptor Signaling to Treat Fragile X Syndrome

March 7, 2019

FRAXA-backed work revealed NMDA receptors may hold the key to correcting brain signaling in Fragile X, pointing to new treatment strategies.

Antonella Borreca, PhD, and Alberto Martire, PhD

Coffee, Tea, and Chocolate: Adenosine Receptors in Fragile X

December 11, 2018

Could “caffeine-like” drugs help Fragile X? FRAXA funded research to test adenosine blockers, which may boost thinking and improve symptoms in Fragile X mice.

Investigating Gene Reactivation to Treat Fragile X Syndrome

September 22, 2017

With a $180,000 grant from FRAXA Research Foundation, Dr. Jeannie Lee and her team at Harvard are working to reactivate the gene that is silenced in Fragile X syndrome.

Paul Lombroso, PhD, Yale University, FRAXA Investigator

Inhibitors of STEP as a Novel Treatment of Fragile X Syndrome

February 26, 2015

STEP inhibition reversed behavioral and synaptic Fragile X deficits in mice (Neuropharmacology, 2018), highlighting STEP as a promising treatment target.

Social Behavior as an Outcome Measure for Fragile X Clinical Trials

September 13, 2013

FRAXA funding helped identify reliable social behavior tests in Fragile X mice and showed an mGluR5 treatment could improve sociability, guiding future trials.

What Works, and What Doesn’t

September 7, 2012

Early on, no one knew which path would work. Now the results are clear, and they’re directing FRAXA toward the next major Fragile X treatment breakthrough.

AMPAkines and BDNF in Fragile X: UCI Researchers Restore Memory Process in Fragile X

February 14, 2008

FRAXA’s $104K grant supported Dr. Julie Lauterborn at UC in studying dendritic spines and memory-related treatment targets in Fragile X mice.

Richard Paylor, PhD, at Baylor College of Medicine, FRAXA Research grant

Therapeutic Interventions in FMR1 Knockout and Transgenic Mice: Role of the FMR1 Gene

February 13, 2006

With FRAXA’s $229K grant, Baylor researchers showed that Fragile X protein levels in the brain affect activity and anxiety in mice and humans.

Improving Memory Reversal Testing and Treatment with AMPAkines in the Fragile X Knock-Out Mouse

June 27, 1998

FRAXA-funded Dr. W. Ted Brown studied learning deficits in Fragile X mice and tested Ampakine drugs for potential treatment.

Correcting Fragile X Syndrome Deficits by Targeting Neonatal PKCε Signaling in the Brain

Cellular-Specific Therapeutic Targeting of Inhibitory Circuits in Fragile X Syndrome

Auditory Dysfunction in Fragile X Syndrome in a Mouse Model of Fragile X

Clinical Trials and Cyclic AMP in Fragile X Syndrome: A Life Journey

Correcting Sensory Processing in Fragile X Mice by Modulating Kv3.1

Developmental Profile of Glutamatergic Synapses in Fragile X

Enhancing NMDA Receptor Signaling to Treat Fragile X Syndrome

Coffee, Tea, and Chocolate: Adenosine Receptors in Fragile X

Investigating Gene Reactivation to Treat Fragile X Syndrome

Inhibitors of STEP as a Novel Treatment of Fragile X Syndrome

Social Behavior as an Outcome Measure for Fragile X Clinical Trials

What Works, and What Doesn’t

AMPAkines and BDNF in Fragile X: UCI Researchers Restore Memory Process in Fragile X

Therapeutic Interventions in FMR1 Knockout and Transgenic Mice: Role of the FMR1 Gene

Improving Memory Reversal Testing and Treatment with AMPAkines in the Fragile X Knock-Out Mouse

Support FRAXA

Get In Touch!

Explore Fragile X & Research

Get FRAXA Updates